Duchenne Gene Therapy Firm Sarepta Therapeutics' Earns 8% Price Target Hike From This Analyst

Earlier today, Sarepta Therapeutics Inc SRPT announced that it would submit the marketing application and seek accelerated FDA approval for SRP-9001 in Duchenne Muscular Dystrophy (DMD) this fall.
Sarepta’s data disclosures earlier this month showed statistically significant functional improvements across company studies compared to an external, matched control, Needham wrote.
The analyst increased the price target from $150 to $162, reflecting an increase in expected EPS for 2025.
Needham is bullish based on emerging data across SRP-9001 studies has shown clinical benefit, especially when considered against matched natural history.
Related: Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial.
The analyst believes SRP-9001 has the most manageable toxicity profile of all AAV-based gene therapies in DMD.
Needham expects a high likelihood for an advisory committee ahead of approval. Likely, safety data from the ongoing EMBARK study will also be included in Adcomm materials.
The analyst anticipates the application acceptance (~2 months post-filing) to de-risk SRP-9001, proceeding to an accelerated approval and potential launch in 2H of 2023.
Price Action: SRPT shares are up 8.16% at $92.95 during the market session on the last check Friday.